All patients
age >= 60 yr age >= 65 yr corticosteroids: no corticosteroids: yes invasive ventilation non invasive oxygen subjects at risk
antiviral and associated therapy in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Hung et al., 2020 0.47 [0.01; 24.30]
Nojomi, 2020 2.04 [0.18; 23.27]
Nojomi, 2020 0.49 [0.04; 5.58]
Solaymani-Dodaran, 2021 1.22 [0.66; 2.26]
1.17 [0.66 ; 2.08 ] Hung et al., 2020, Nojomi, 2020, Nojomi, 2020, Solaymani-Dodaran, 2021 4 0% 700 moderate not evaluable clinical improvementdetailed results Huang, 2020 1.37 [0.73; 2.56]
Hung et al., 2020 3.92 [1.66; 9.24]
2.22 [0.80 ; 6.20 ] Huang, 2020, Hung et al., 2020 2 73% 149 moderate not evaluable clinical improvement (14-day)detailed results Huang, 2020 1.37 [0.73; 2.56]
1.37 [0.73 ; 2.56 ] Huang, 2020 1 0% 22 NA not evaluable clinical improvement (time to event analysis only)detailed results Hung et al., 2020 3.92 [1.66; 9.24]
Solaymani-Dodaran, 2021 0.94 [0.75; 1.17]
1.80 [0.45 ; 7.27 ] Hung et al., 2020, Solaymani-Dodaran, 2021 2 90% 507 moderate not evaluable hospital dischargedetailed results Huang, 2020 2.00 [1.15; 3.47]
2.00 [1.15 ; 3.47 ] Huang, 2020 1 0% 22 NA not evaluable mechanical ventilationdetailed results Solaymani-Dodaran, 2021 1.62 [0.85; 3.08]
1.62 [0.85 ; 3.08 ] Solaymani-Dodaran, 2021 1 0% 373 NA not evaluable radiologic improvement (14-day)detailed results Huang, 2020 1.33 [0.94; 1.88]
1.33 [0.94 ; 1.88 ] Huang, 2020 1 0% 22 NA not evaluable radiologic improvement (7-day)detailed results Huang, 2020 2.40 [0.26; 22.51]
2.40 [0.26 ; 22.51 ] Huang, 2020 1 0% 22 NA not evaluable viral clearance detailed results Huang, 2020 1.20 [0.78; 1.85]
Hung et al., 2020 4.37 [1.86; 10.25]
2.17 [0.61 ; 7.66 ] Huang, 2020, Hung et al., 2020 2 86% 149 moderate not evaluable viral clearance (time to event analysis only)detailed results Hung et al., 2020 4.37 [1.86; 10.25]
4.37 [1.86 ; 10.25 ] Hung et al., 2020 1 0% 127 NA not evaluable viral clearance by day 14detailed results ELACOI (Lopinavir/ritonavir), 2020 1.84 [0.40; 8.38]
Huang, 2020 1.09 [0.95; 1.26]
1.10 [0.95 ; 1.26 ] ELACOI (Lopinavir/ritonavir), 2020, Huang, 2020 2 0% 91 moderate not evaluable viral clearance by day 7detailed results ELACOI (Lopinavir/ritonavir), 2020 1.08 [0.41; 2.89]
Huang, 2020 1.20 [0.60; 2.40]
1.16 [0.66 ; 2.04 ] ELACOI (Lopinavir/ritonavir), 2020, Huang, 2020 2 0% 91 moderate not evaluable ICU admissiondetailed results Solaymani-Dodaran, 2021 1.23 [0.70; 2.18]
1.23 [0.70 ; 2.18 ] Solaymani-Dodaran, 2021 1 0% 373 NA not evaluable severe COVID-19 occurrencedetailed results ELACOI (Lopinavir/ritonavir), 2020 0.30 [0.07; 1.27]
0.30 [0.07 ; 1.27 ] ELACOI (Lopinavir/ritonavir), 2020 1 0% 69 NA not evaluable serious adverse eventsdetailed results Hung et al., 2020 0.23 [0.01; 7.12]
0.23 [0.01 ; 7.12 ] Hung et al., 2020 1 0% 127 NA not evaluable adverse eventsdetailed results Huang, 2020 1.80 [0.14; 23.37]
1.80 [0.14 ; 23.37 ] Huang, 2020 1 0% 22 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-04 01:57 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814
- roots T: 290
